This profile has not been claimed and data may not be accurate.
81st percentile
61st percentile
Founder Matrix
Most Like You
Most Complimentary
Credibility
Traction · 83th percentile
- Benchling has raised $412M in total funding across 9 funding rounds.
Founder score
- 99%Probability of being accurate (99%)Current Founder and CEO of Benchling, a role he has held since 2012.
- 99%Probability of being accurate (99%)Benchling is a Y Combinator Summer 2012 company.
- 95%Probability of being accurate (95%)Sajith co-founded Benchling alongside at least one other co-founder.
- 92%Probability of being accurate (92%)Benchling has raised $412M in total funding across 9 funding rounds.
Investor score
- 80%Probability of being accurate (80%)Publicly identified as an angel investor with a portfolio that includes Alleviate Health.
- 75%Probability of being accurate (75%)Has made at least one confirmed angel investment (Alleviate Health).
- 45%Probability of being accurate (45%)Approximately 5 or more years of investing experience based on known angel activity since at least 2019.
What you likely need
You are the founder and CEO of Benchling, a $6B+ unicorn in life-science software with $412M raised and a 13-year track record — your founder profile is exceptionally strong. Your next inflection point is likely an IPO or major strategic milestone, and your angel investing activity is nascent relative to your network and credibility. Expanding your public presence and investor relationships now will maximize optionality for both a liquidity event and a more active investing career.
Are these your current priorities?
We will tune and customize your Founder Festival experience to make sure you get invited to the events that would be most valuable to you.
- fundraisingBegin IPO readiness preparations — Benchling's $6B+ valuation, $412M raised, and 13-year operating history make it a strong public-market candidate, and the current biotech/SaaS window rewards early preparation.
- introsLeverage your YC S12 alumni status to access YC's late-stage founder community and Continuity fund relationships, which can be valuable for pre-IPO secondary or strategic partnership introductions.
- introsExpand your angel investing portfolio beyond a single known investment — your domain expertise in biotech R&D software gives you a differentiated edge in evaluating life-science tooling startups.
- positioningPublish long-form content or speak at major biotech conferences about AI for science — your LinkedIn posts on AI Scientist and FDA modernization already resonate and can be amplified into a stronger public voice.
- positioningPublicly communicate Benchling's path to $100M ARR if not already disclosed — crossing that milestone publicly would significantly strengthen your IPO narrative and press coverage.
- tacticalDeepen integrations with major pharma and CRO partners beyond Twist Bioscience and Ginkgo Bioworks to build the enterprise moat that supports a premium public-market multiple.
- hiringWith 642 employees and strong growth, focus on hiring senior go-to-market and finance leadership now to support the operational rigor required for a public company.